免疫实践咨询委员会关于重组佐剂带状疱疹亚单位疫苗建议的成本效益
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.
作者信息
Le Phuc, Rothberg Michael B
机构信息
Center for Value-Based Care Research, Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
出版信息
JAMA Intern Med. 2018 Sep 1;178(9):1277-1278. doi: 10.1001/jamainternmed.2018.3200.
Abstract
This cost-effectiveness study evaluates use of the recombinant adjuvanted zoster subunit vaccine among patients 50 years and older.
摘要
这项成本效益研究评估了重组佐剂带状疱疹亚单位疫苗在50岁及以上患者中的使用情况。
相似文献
1
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.免疫实践咨询委员会关于重组佐剂带状疱疹亚单位疫苗建议的成本效益
JAMA Intern Med. 2018 Sep 1;178(9):1277-1278. doi: 10.1001/jamainternmed.2018.3200.
2
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
3
Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.带状疱疹疫苗对 50 岁人群的成本效益分析
Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.
4
Recent Updates to the Advisory Committee On Immunization Practices Recommendations for Pneumococcal and Herpes Zoster Vaccination.免疫实践咨询委员会关于肺炎球菌和带状疱疹疫苗接种建议的最新更新。
R I Med J (2013). 2020 Aug 3;103(6):34-37.
5
Update on recommendations for use of herpes zoster vaccine.带状疱疹疫苗使用建议的更新
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31.
6
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.《免疫功能低下的成年（≥19 岁）人群使用重组带状疱疹疫苗：免疫接种实践咨询委员会的建议-美国，2022 年》。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84. doi: 10.15585/mmwr.mm7103a2.
7
Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.免疫实践咨询委员会关于带状疱疹疫苗使用建议的最新情况。
J Am Osteopath Assoc. 2011 Oct;111(10 Suppl 6):S31-3.
8
Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.香港老年人接种带状疱疹亚单位佐剂疫苗的潜在成本效益。
Vaccine. 2018 Jul 25;36(31):4610-4620. doi: 10.1016/j.vaccine.2018.06.049. Epub 2018 Jun 27.
9
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.美国老年人中佐剂重组带状疱疹疫苗的成本效益。
Vaccine. 2018 Aug 9;36(33):5037-5045. doi: 10.1016/j.vaccine.2018.07.005. Epub 2018 Jul 14.
10
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.欣格来福：新型佐剂重组带状疱疹疫苗。
Ann Pharmacother. 2018 Jul;52(7):673-680. doi: 10.1177/1060028018758431. Epub 2018 Feb 18.
引用本文的文献
1
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.带状疱疹重组疫苗（RZV）预防带状疱疹的成本效益：更新的关键评价。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2168952. doi: 10.1080/21645515.2023.2168952. Epub 2023 Mar 14.
2
Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis.各世界卫生组织区域带状疱疹疫苗接种意愿及其相关因素：全球系统评价和荟萃分析。
JMIR Public Health Surveill. 2023 Mar 9;9:e43893. doi: 10.2196/43893.
3
Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review.美国带状疱疹疫苗的成本效益：一项系统评价。
Prev Med Rep. 2022 Jul 22;29:101923. doi: 10.1016/j.pmedr.2022.101923. eCollection 2022 Oct.
4
Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.免疫功能正常的老年人接种带状疱疹疫苗的成本效益：佐剂亚单位疫苗与减毒活疫苗的比较。
BMC Med. 2018 Dec 6;16(1):228. doi: 10.1186/s12916-018-1213-5.
本文引用的文献
1
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
2
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.带状疱疹亚单位佐剂疫苗在老年人中的成本效益。
JAMA Intern Med. 2018 Feb 1;178(2):248-258. doi: 10.1001/jamainternmed.2017.7431.
3
Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.带状疱疹疫苗加强针在美对当前已接种人群的成本效益分析
Am J Prev Med. 2017 Dec;53(6):829-836. doi: 10.1016/j.amepre.2017.08.029.
4
Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.2015年美国成年人群疫苗接种覆盖率监测
MMWR Surveill Summ. 2017 May 5;66(11):1-28. doi: 10.15585/mmwr.ss6611a1.
5
Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.带状疱疹疫苗对 50 岁人群的成本效益分析
Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.
6
Barriers to the use of herpes zoster vaccine.带状疱疹疫苗使用障碍。
Ann Intern Med. 2010 May 4;152(9):555-60. doi: 10.7326/0003-4819-152-9-201005040-00005.
Zotero 插件